| AJNMMI Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
Am J Nucl Med Mol Imaging 2012;2(1):xx-xx.
Original Article
Combined SPECT and multidetector CT for prostate cancer evaluations
Carina Mari Aparici, David Carlson, Nhan Nguyen, Randall A. Hawkins, Youngho Seo
Center for Molecular and Functional Imaging, Department of Radiology and Biomedical Imaging, University of California, San
Francisco, CA, USA; .Nuclear Medicine Service, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA; UC Berkeley
– UCSF Graduate Program in Bioengineering, University of California, Berkeley and San Francisco, CA, USA; Department of
Radiation Oncology, Helen Diller Family Comprehensive Cancer Canter, Uni-versity of California, San Francisco, CA, USA.
Received September 20, 2011; accepted September 25, 2011; Epub September, 2011; Published October, 2011
Abstract: 111In-capromab pendetide is an imaging probe for noninvasive detection of prostate cancer dissemination, and can be
difficult to interpret because of low photon statistics resulting in noisy images with limited anatomical precision. We examined if a 16-
slice multidetector computed tomography (MDCT) combined with single photon emission computed tomography (SPECT) could
increase the impact on the clinical management and improve confidence in SPECT image interpretations in comparison to a
relatively low-mA (limited resolution) CT. 17 scans were reviewed from a SPECT combined with low-mA CT scanner; 21 scans were
reviewed from a SPECT combined with 16-slice MDCT scanner. Reports of the clinical interpretations from the imaging studies,
additional examinations performed by referring physicians as a follow-up to the imaging results, and long-term clinical and
laboratory follow-ups were used to define confidence of the SPECT/CT readings and impact of the readings on the patient man-
agement. The impact was defined as: the occurrence of the 111In-capromab pendetide interpretation resulted in additional imaging
studies or biopsies. MDCT improved the quality and confidence in the characterization of small lymph nodes with or without up-take
of 111In-capromab pendetide. The increased confidence with MDCT in SPECT/CT readings was evident in all cases reviewed in this
study, and the impact on the clinical management was higher (8 out of 21) using SPECT/MDCT than the impact using SPECT
combined with low-mA CT (2 out of 17). The dual-modality SPECT/CT provides a quantifiable benefit when MDCT is used instead of
low-mA CT, particularly for pros-tate cancer evaluations using 111In-capromab pendetide. (ajnmmi1109001).
Keywords: prostate cancer, capromab pendetide, SPECT/CT, MDCT, prostate specific membrane antigen (PSMA)
Full text PDF
Address all correspondence to:
Dr. Youngho Seo
UCSF Physics Research Laboratory
Department of Radiology and Biomedical Imaging
University of California, San Francisco, CA, USA.
E-mail: youngho.seo@ucsf.edu
Original Article
Combined SPECT and multidetector CT for prostate cancer evaluations
Carina Mari Aparici, David Carlson, Nhan Nguyen, Randall A. Hawkins, Youngho Seo
Center for Molecular and Functional Imaging, Department of Radiology and Biomedical Imaging, University of California, San
Francisco, CA, USA; .Nuclear Medicine Service, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA; UC Berkeley
– UCSF Graduate Program in Bioengineering, University of California, Berkeley and San Francisco, CA, USA; Department of
Radiation Oncology, Helen Diller Family Comprehensive Cancer Canter, Uni-versity of California, San Francisco, CA, USA.
Received September 20, 2011; accepted September 25, 2011; Epub September, 2011; Published October, 2011
Abstract: 111In-capromab pendetide is an imaging probe for noninvasive detection of prostate cancer dissemination, and can be
difficult to interpret because of low photon statistics resulting in noisy images with limited anatomical precision. We examined if a 16-
slice multidetector computed tomography (MDCT) combined with single photon emission computed tomography (SPECT) could
increase the impact on the clinical management and improve confidence in SPECT image interpretations in comparison to a
relatively low-mA (limited resolution) CT. 17 scans were reviewed from a SPECT combined with low-mA CT scanner; 21 scans were
reviewed from a SPECT combined with 16-slice MDCT scanner. Reports of the clinical interpretations from the imaging studies,
additional examinations performed by referring physicians as a follow-up to the imaging results, and long-term clinical and
laboratory follow-ups were used to define confidence of the SPECT/CT readings and impact of the readings on the patient man-
agement. The impact was defined as: the occurrence of the 111In-capromab pendetide interpretation resulted in additional imaging
studies or biopsies. MDCT improved the quality and confidence in the characterization of small lymph nodes with or without up-take
of 111In-capromab pendetide. The increased confidence with MDCT in SPECT/CT readings was evident in all cases reviewed in this
study, and the impact on the clinical management was higher (8 out of 21) using SPECT/MDCT than the impact using SPECT
combined with low-mA CT (2 out of 17). The dual-modality SPECT/CT provides a quantifiable benefit when MDCT is used instead of
low-mA CT, particularly for pros-tate cancer evaluations using 111In-capromab pendetide. (ajnmmi1109001).
Keywords: prostate cancer, capromab pendetide, SPECT/CT, MDCT, prostate specific membrane antigen (PSMA)
Full text PDF
Address all correspondence to:
Dr. Youngho Seo
UCSF Physics Research Laboratory
Department of Radiology and Biomedical Imaging
University of California, San Francisco, CA, USA.
E-mail: youngho.seo@ucsf.edu
 |  |  |  |  |  |  |